Live price temporarily unavailable.
Alto Neuroscience (ANRO) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|
| Income statement | |||
| Operating income | −$37.8M | −$68.6M | −$66.4M |
| Net income | −$36.3M | −$61.4M | −$63.2M |
| EPS (diluted) | −$9.73 | −$2.50 | −$2.19 |
| Balance sheet | |||
| Cash and equivalents | $82.5M | $168.2M | $176.5M |
| Total assets | $86.6M | $177.5M | $184.7M |
| Total liabilities | $16.8M | $26.1M | $33.5M |
| Long-term debt | $9.86M | $10.3M | $16.2M |
| Shareholders' equity | −$71.7M | $151.5M | $151.1M |
| Cash flow | |||
| Operating cash flow | −$33.4M | −$47.4M | −$51.8M |
| Capital expenditure | $470.0K | $2.08M | $24.0K |
| Free cash flow | −$33.9M | −$49.5M | −$51.8M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$18.9M | −$17.0M | −$15.7M | −$18.7M | −$15.0M | −$17.1M | −$27.1M | −$29.1M |
| Net income | −$16.8M | −$15.2M | −$15.2M | −$17.7M | −$14.2M | −$16.2M | −$26.2M | −$27.6M |
| EPS (diluted) | −$0.62 | −$0.52 | −$0.56 | −$0.65 | −$0.52 | −$0.46 | −$0.80 | −$0.65 |
| Balance sheet | ||||||||
| Cash and equivalents | $181.7M | $168.2M | $160.8M | $147.6M | $137.8M | $176.5M | $263.8M | $243.7M |
| Total assets | $191.6M | $177.5M | $171.9M | $157.9M | $147.0M | $184.7M | $276.3M | $254.1M |
| Total liabilities | $26.6M | $26.1M | $32.8M | $34.5M | $35.4M | $33.5M | $32.9M | $34.8M |
| Long-term debt | $6.63M | $10.3M | $19.9M | $20.1M | $20.3M | $16.2M | $13.9M | $12.4M |
| Shareholders' equity | $165.1M | $151.5M | $139.1M | $123.4M | $111.6M | $151.1M | $243.4M | $219.2M |
| Cash flow | ||||||||
| Operating cash flow | −$11.7M | −$13.0M | −$16.6M | −$13.8M | −$9.92M | −$11.5M | −$27.1M | −$19.8M |
| Capital expenditure | $1.00M | $506.0K | $24.0K | $0 | $0 | $0 | $556.0K | $0 |
| Free cash flow | −$12.7M | −$13.5M | −$16.6M | −$13.8M | −$9.92M | −$11.5M | −$27.6M | −$19.8M |
From Alto Neuroscience's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Alto Neuroscience in our feed yet.